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ABSTRACT  
Aging is characterized by progressive loss of functions and accumulation of metabolic 
by-products, including advanced glycation end products (AGEs), which are observed in 
several pathological conditions. A number of waste macromolecules, including AGEs are 
taken up from the circulation by endocytosis mainly in liver sinusoidal endothelial cells 
(LSECs) and Kupffer cells (KCs). However, AGEs still accumulate in tissues with age. 
The aim of the present study was to determine whether the efficiency of LSECs and KCs 
for disposal of AGEs changes through aging.  
Results: After intravenous administration of 14C-AGE-albumin in pre-pubertal, young 
adult, middle aged and old mice, more than 90% of total recovered 14C-AGE was liver 
associated, irrespective of age. LSECs and KCs represented the main site of uptake. A 
fraction of the 14C-AGE degradation products (14C-AGE-DPs) was stored for months in 
the lysosomes of these cells after uptake. The overall rate of 14C-AGE-DPs removal from 
the liver was markedly faster in pre-pubertal than in all post-pubertal age groups. The 
ability to dispose of 14C-AGE-DPs decreased to similar extents after puberty in LSECs 
and KCs. A fast early removal phase was characteristic for all age groups except the old 
group, where this phase was absent.  
Conclusions: Removal of AGE-DPs from the liver scavenger cells is a very slow process 
that changes with age. The ability of these cells to dispose of AGEs declines after 
puberty. Decreased AGE removal efficiency early in life may lead to AGE accumulation. 
Highlights: !  14C-AGE allows long term tracking of intracellular metabolism of the 
AGE-adduct !  AGE degradation products (AGE-DPs) accumulate in lysosomes of liver 
scavenger cells !  Liver scavenger cell discharge of AGE-DPs decreases after puberty 
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1. Introduction 
Advanced glycation end-products (AGEs) are heterogeneous compounds formed by non-
enzymatic, irreversible glycosylation/glycoxydation of proteins (Baynes and Thorpe, 
1999; Horie et al., 1997; Ling et al., 1998). This modification alters protein 
characteristics and renders them resistant to proteolysis (Miyata et al., 1997; Sell et al., 
1996). Accumulation of AGEs in tissues is harmful (Baynes and Thorpe, 1999; Makita et 
al., 1994), observed in several pathological conditions (Hammes et al., 1999; Horie et al., 
1997; Niwa, 2006), and is thought to result from chronic hyperglycemia, and increased 
oxidative and carbonyl stress (Baynes and Thorpe, 1999; Makita et al., 1994).  
Because AGEs are also formed as by-products of normal metabolic processes, aging is 
associated with higher appearance of AGEs in various tissues including liver (Baynes and 
Thorpe, 1999; Dunn et al., 1991; Hammes et al., 1999; Horie et al., 1997; Ling et al., 
1998; Schleicher et al., 1997). In humans and other mammals the rate of AGE 
accumulation correlates inversely with species longevity (Sell et al., 1996). AGEs 
accumulate faster in shorter-lived compared with longer-lived mouse strains (Sell and 
Monnier, 1997). However, it is not clear whether AGE accumulation is a cause of aging 
or a consequence of age-related decline in their elimination, or both.  
Intravenously administered AGE modified bovine serum albumin (AGE-BSA) is rapidly 
removed from the circulation via scavenger receptor-mediated endocytosis in the liver 
scavenger cells, i.e. liver sinusoidal endothelial cells (LSECs) and Kupffer cells (KCs) 
(Smedsrod et al., 1997). However, AGEs still accumulate in tissues with age. The aim of 
the present study was to determine whether the effiency of liver scavenger cells for 
disposal of accumulated AGE wastes changes through maturation and aging. The liver 
handling of AGEs was examined in four age groups of C57BL/6 mice; prepubertal, 
young adult, middle aged and old mice. 
All previous studies on the turnover of AGEs have been carried out using AGE-proteins 
tagged with 125I in the protein part. When 125I-AGE-proteins are subjected to lysosomal 
proteolysis, the radioactive tag is rapidly released and disappears from the site of uptake, 
leaving the remaining parts undetectable. In addition, the short half-life of 125I makes 
long-term studies impossible. To keep track of the AGEs during the entire degradation 
process following endocytosis, a stabile tagging of the AGE-adduct proper was 
developed. Using this tracer facilitated the observation that the ability of the liver 
scavenger cells to dispose of AGEs declined markedly after puberty, and then changed 
little up to high age. 
 
2. Materials and methods 
2.1. Reagents 
Collagenase-P and protease inhibitors were from Roche Diagnostics GmbH. Fatty acid 
free BSA (99% purity), and RPMI-1640 medium were from Sigma. Percoll, and D-(U-
14C)-Glucose 323mCi/mmol were from Amersham–Pharmacia Biotech. Tissue solubilizer 
“Solvable” and “Ultima Gold” scintillation cocktail were from PerkinElmer. 
2.2. Animals  
Male C57Bl/6J mice, 14 and 28 months old, were purchased from Aged Rodent Colonies, 
National Institute on Aging (NIA), USA. C57Bl/6J mice, 3 months old were from 
Charles River Laboratories. Pre-pubertal (0.8 months old) males were obtained by 
breeding C57Bl/6J mice from Charles River Laboratories. In the hepatocellular 
distribution study, 0.8 months and 3 months old C57BL/6N males from Harlan were 
used. Prior to ligand administration, the mice were anaesthetized with fentanyl and 
fluanizon (HypnormTM, Janssen Pharmaceutical), in combination with midazolam 
(DormicumTM, Roche). The study was approved by the Norwegian Ethics Committee for 
Research on Animals.  
Four age groups of animals were chosen for the study: pre-pubertal (0.8 months old), 
young-adult (3 months old), middle-age (14 months old) and old (28 months old), 
corresponding to 9, 25, 50, and 80 years of human age respectively (Supplementary 
Fig.1). 
2.3. Ligand Preparation 
BSA (50mg/ml) was incubated with 75mM 14C-glucose in 0.33M disodium hydrogen 
phosphate/NaOH buffer (pH11) for two weeks at 50˚C. The total volume of the 
incubation mixture was 42µl. Non-incorporated 14C-glucose was removed by size 
exclusion chromatography on Superdex-70 column (Amersham–Pharmacia Biotech). The 
resulting 14C-AGE-BSA carried specific radioactivity (420000dpm/µg) sufficient for long 
term tracking of intracellular metabolism of the AGE-adduct. 
Following intravenous injection of 14C-AGE-BSA, the rate of blood clearance was found 
to be similar to what was reported for 125I-AGE-BSA (Smedsrod et al., 1997; Svistounov 
et al., 2003), with all injected radioactivity eliminated from circulation within 5min 
(Supplementary Fig.2). 
2.4. Anatomical Distribution of 14C-AGE-BSA  
14C-AGE-BSA (4.7μg, 2x106dpm) was injected into the tail vein of anaesthetized pre-
pubertal (n=9), young-adult (n=6) and old mice (n=7) via catheter allowing precise 
administration. Animals were killed at 1.5h, 24h, 1, 2, 3, 4, 5, or 8 weeks after injection. 
Organs were extirpated, solubilized in “Solvable” and their radioactivity measured in a 
Packard Liquid Scintillation Counter using “Ultima Gold”. 
In a preliminary study performed in young-adult (n=3), middle-aged (n=3) and old mice 
(n=1) at 1.5h, 24h and 1 week after injection, carcasses without internal organs were 
found to contain 11% of total recovered radioactivity without any difference between the 
age groups or the time points after ligand administration, while internal organs contained 
89% of the radioactivity. Radioactivity in the carcasses was quantified by combustion 
analysis in a Packard Sample Oxidizer. 
2.5. 14C-AGE-BSA Hepatic Disposal  
Pre-pubertal (n=28), young-adult (n=27), middle-aged (n=29) and old mice (n=23) were 
injected with 14C-AGE-BSA (4.7μg, 2x106dpm) as described above. The livers were 
collected at 1.5, 6, 12, 24, 48 h and 0.5, 1, 1.5, 2, 3.5, 5, 8 and 12 weeks after injection. 
Up to six animals were killed at each time point per age group for measurement of liver 
radioactivity.  
2.6. Hepatocellular Distribution of 14C-AGE-BSA  
Animals from pre-pubertal and young-adult groups were injected with 14C-AGE-BSA 
(9.4µg/animal) via a catheter into the tail vein, and killed 10min or 4 weeks post-
injection. PCs, KCs and LSECs were isolated(Hansen et al., 2002; Smedsrod and Pertoft, 
1985) and maintained in RPMI-1640 for 1h prior to assessment of cell numbers (average 
cell counts from 13 random 0.04 mm2 squares per culture). The cultured cells were then 
solubilized for radioactivity measurement.  
2.7. Subcellular Fractionation 
Five weeks after 14C-AGE-BSA injection, livers of terminally anaesthetized, overnight-
fasted mice were perfused with ice-cold buffer until bloodless, excised and homogenized 
by mild mechanical force in Dounce homogenizer (Bellco Glass) in 0.25M sucrose 
containing 20mM Hepes pH 7.4, 10mM EDTA and protease inhibitors. The post-nuclear 
supernatants were centrifuged through linear sucrose gradient (21-54% W/W) for 5h at 
85000g followed by fraction collection. All the steps were carried out at 4˚C. Fraction 
densities were calculated from refractive indices (Rickwood and Graham, 1997). 
Radioactivity and activity of acid DNAse ((a lysosomal marker) (Wattiaux et al., 1993)) 
were assayed in fraction aliquots.  
2.8. Size Exclusion Chromatography 
Animals were placed in metabolic cages for a 12h period up to 5 weeks after 14C-AGE-
BSA injection. Collected urine was stored at -70˚C. Size distribution of urinary 14C-AGE-
DPs collected at 1, 2, 6, 18, 29 and 36 days after injection, was analysed using DIONEX 
HPLC system with “Superdex-Peptide” column (GE Healthcare) and “Radioactivity flow 
detector for HPLC LB 509” (BERTHOLD TECHNOLOGIES). Molecular weights of the 
14C-AGE-DPs were calculated from the standard curve generated by plotting the retention 
time of the manufacturer recommended standards against their corresponding molecular 
weights.  
2.9. Data Analysis 
The liver 14C-AGE-associated radioactivity (expressed as % dose) versus time data were 
analyzed using non-linear regression (Prism-4, GraphPad Software). The model that best 
described the radioactivity disposal data was selected using the Akaike’s Information 
Criterion (AIC) (Fig.2). The differences between age groups were determined by 
comparing best-fit values of parameters such as C and half-life using the F-test (Tab.1).  
The hepatocellular distribution of 14C-AGEs data was analyzed by one–way ANOVA and 
Tukey HSD posthoc tests, using the SPSS software (Fig.3).  
3. Results  
3.1. Ligand Preparation 
Tagging of AGE with 125I in the protein moiety has the serious disadvantage that the 
tracer is rapidly lost when the protein moiety is subjected to endo/lysosomal proteolysis, 
leaving the AGE-adducts undetectable. We developed a microscale method for 
incorporation of 14C in AGE-adducts based on published techniques (He et al., 1999), but 
with improved glucose to protein conjugation. The resulting 14C-AGE-BSA allowed for 
the first time studies on the intracellular metabolism of the AGE-adduct proper.  
3.2. Anatomical Distribution of Intravenously Administered 14C-AGE-BSA 
The organ distribution of intravenously injected 14C-AGE-BSA was measured in pre-
pubertal, young-adult, and old mice at 1.5h, 24h, 1 week and at 3-5 time points up to 8 
weeks after injection. More than 90% of the total recovered radioactivity was liver 
associated, irrespective of age and time after injection (Fig.1). A previous study similarly 
showed that most of the injected AGE-BSA labelled with 125I in the protein part 
distributed in liver of young mice (Svistounov et al., 2003). 
3.3. Hepatic Disposal of 14C-AGE 
The most striking finding was that the overall rate of 14C-AGE removal from the liver 
was markedly faster in pre-pubertal than in older individuals (Fig.2). Moreover, 14C-AGE 
degradation products (14C-AGE-DPs) were stored for months in the liver. There was also 
a slowdown in the early stage of 14C-AGE disposal in old age (Fig.2-insert).  
Applying non-linear regression analysis of the clearance data in Fig.2 allowed the 
following interpretations (Tab.1): i) a three-phase exponential decay model provided the 
best description of liver radioactivity-time relationship for pre-pubertal, young-adult and 
middle-age groups (99% probability), whereas a two-phase exponential decay model 
fitted the old group with 97% probability (AIC test). ii) Removal of 14C-AGEs from the 
liver proceeded through three phases: initial (fastest), intermediate and terminal (slowest) 
in all groups except the oldest. iii) A substantial proportion of radioactivity was removed 
during the initial phase (C1 Tab.1). Rapid removal rates made the total exposure of livers 
to AGEs very low during this phase as reflected by area under the curve (AUC1 Tab.1). 
This phase was not observed in the old-age group. iv) Most of the 14C-AGE-DPs were 
removed during the intermediate phase (C2 Tab.1). Relatively rapid removal made the 
exposure to 14C-AGE-DPs moderate in this phase except for the pre-pubertal group where 
exposure was highest in the intermediate phase (AUC2 Tab.1). v) Although the lowest 
proportion of radioactivity was removed during the terminal phase (C3 Tab.1), the very 
slow removal in all post-pubertal groups (half-life3 Tab.1) resulted in the highest exposure 
to the 14C-AGE-AGEs in this phase (AUC3 Tab.1). vi) In the pre-pubertal animals the 
lowest proportion of 14C-AGE-DPs, disposed of through the terminal phase (C3 Tab.1) in 
combination with its relatively short half-life (half-life3 Tab.1), resulted in a markedly 
lower exposure of livers to AGE-DPs compared with other groups during the terminal 
phase (AUC3 Tab.1) and even to the intermediate phase in the same group (AUC2 Tab.1). 
vii) The proportion removed during the terminal phase increased markedly with age (C3 
Tab.1). The changes in removal rate in this phase resembled the pattern observed for the 
intermediate phase (C2 Tab.1).  
3.4. Hepatocellular Distribution of 14C-AGE  
The greatest age-related difference in the rate of disposal of 14C-AGEs from liver 
occurred between the pre-pubertal and young-adult mouse groups (Fig. 2). We therefore 
performed hepatocellular distribution studies in these two age groups. PC, KC and LSEC 
cultures were prepared 10 min and 4 weeks after intravenous injection of 14C-AGE-BSA 
in pre-pubertal and young-adult mice. In both age groups, and at both time points, most 
of the radioactivity was located in LSECs and KCs (Fig. 3A, B), with very little 
radioactivity in PCs.  
Ten minutes after ligand injection, the radioactivity per LSEC was higher in pre-pubertal 
animals, probably reflecting fewer LSECs than in young-adult mice due to smaller liver 
size, whereas no difference in radioactivity per KC was detected (Fig.3A).  
At 4 weeks post-injection the remaining radioactivity per LSEC and KC was significantly 
higher in the young-adult than in the pre-pubertal groups (Fig.3B), supporting the 
observation of fastest AGE-DPs removal in the pre-pubertal group. The results further 
show that the cell efficacy to eliminate AGE-DPs after uptake decreases both in LSECs 
and KCs after puberty.  
3.5. Subcellular Localisation of 14C-AGE 
All radioactive material in the gradients originated from KCs and LSECs. At the same 
time only about 50% of acid DNAse was derived from KCs and LSECs while the rest 
originated from PC (Wattiaux et al., 1993). Lysosomes from all three cell types normally 
band at the same density on sucrose gradient (Wattiaux et al., 1993). 
Subcellular fractionation of liver homogenates at 5 weeks post-injection revealed 
radioactivity peaks banding at virtually the same sucrose gradient density in all the age 
groups (Fig.4A-D). The lysosomal marker acid DNAse banded at a markedly lower 
density compared with the position of the radioactivity peak in pre-pubertal group 
(Fig.4A). With age, the banded density of acid DNAse gradually shifted towards higher 
density (Fig.4B-C). In the old-age group, the acid DNAse peak co-eluted with the 
radioactivity peak (Fig.4D).  
3.6. Size Distribution of Urinary 14C-AGE-DPs  
Size fractionation of urine samples was performed at 1, 2, 6 and 18 days after 14C-AGE-
BSA injection to analyze the AGE-DPs (Fig. 5). Radioactive material started eluting at 
retention time 53min, corresponding to 12900Da. However, very little material eluted in 
this region. The typical peak width for the “Superdex-Peptide 10/300 GL” column is 5-6 
min at flow rate 0.2ml/min. Therefore, the detected radioactive peaks represented elution 
of heterogeneous material with overlapping molecular size.  
Low MW 14C-AGE-DPs (140-1650Da at “Full width at half maximum” (FWHM)) 
prevailed in the urine samples on day 1 post-injection but pre-pubertal mice exhibited a 
broader MW spectrum of excreted material versus the other age groups (70-2370Da at 
FWHM, Fig.5A). With time, the MW profile of 14C-AGE-DPs in urine became broader 
due to gradual shifting towards a higher MW region (FWHM 210-3700Da at day 18), but 
this shift was more pronounced in the pre-pubertal group (FWHM 260-5410Da at day 
18). Nevertheless, at day 29 post-injection, the MW of 14C-AGE-DPs from post-pubertal 
groups caught up with the pre-pubertal group and the elution profile remained the same 
until day 36 post-injection (not shown). The disappearance of the size difference between 
age groups in urinary 14C-AGE-DPs at 4weeks post-injection can be due to initial and 
intermediate removal phases ending by this time. 
At day 2 post-injection, there was retardation of the shift towards a higher MW region in 
the old-age group (Fig.5B).  
 4. Discussion  
The present study demonstrates a profound difference in the overall rate of hepatic 
disposal of AGE-DPs between pre-pubertal and all post-pubertal age-groups, with a much 
faster AGE-DP elimination in the pre-pubertal animals, and with only minor differences 
between young-adult, middle-age and old mice. Moreover, senescence is associated with 
disappearance of the initial fast phase of AGE-DP disposal. 
 There is a clear difference in the fate of the protein and carbohydrate derived part of 
AGE. The half-life of the protein component of 125I-AGE-BSA internalized by the liver is 
only a few minutes as judged by the speed of release of 125I which tags the protein part of 
AGE (Svistounov et al., 2003). Although degradation is markedly slower in vitro than in 
vivo, more than 50% of 125I-AGE-BSA is degraded and released by cultured LSECs 
already 5-6 h after exposure to the ligand (Smedsrod et al., 1997), whereas, in the present 
study, a time period of 17 to 48 h was required for the liver to dispose of 50% of the 
sequestered 14C-AGE-BSA labelled with 14C in the AGE part. Thus, using 14C-AGE-BSA 
of high specific radioactivity, we show for the first time that the AGE moiety proper is 
stored in the scavenger cells for a much longer time than the protein moiety. 
At 12 weeks post-injection 3.2, 2.8, and 2.1% of the administered 14C-AGE is still left in 
livers of young-adult, middle-age, and old mice, compared to only 0.31% (technically 
complete removal) in pre-pubertal livers. It can be extrapolated that it would take 29, 32 
and 21 weeks to remove AGE-DPs to the level of the pre-pubertal group for the adult, 
middle-age and old-age groups respectively, (corresponding to 27, 30 and 20 years of 
human age (Supplemental Fig.1)). This remarkably prolonged intralysosomal persistence 
of AGE-DPs is due to a very slow terminal disposal phase which is responsible for most 
of the total exposure of liver scavenger cells to AGE-DPs in young-adult, middle-age and 
old groups, whereas in the pre-pubertal group this exposure is 6.5; 4.9 and 7.4 times 
lower, respectively. 
 
The distribution of radioactivity on the gradient reflects the distribution of 14C-AGE-DPs 
in KCs and LSECs whereas the distribution of acid DNAse reflects the distribution of 
lysosomes in both KCs, LSECs and PCs. Although the specific activity of this enzyme is 
18 and 13-fold higher in LSECs and KCs respectively compared to PCs (De Leeuw et al., 
1990), the overall ratio of acid DNAse originating from PCs and sinusoidal cells is 
approximately 50/50 (Wattiaux et al., 1993) because the PCs outmass other cell types in 
liver.  
In all age groups 14C-AGE derived radioactivity bands at the typical density for liver 
lysosomes on sucrose gradients (1.2-1.24g/ml) (1997; Wattiaux et al., 1993). Acid 
DNAse peaks in the typical lysosomal region only in post-pubertal groups. It has been 
claimed that lysosomes from hepatocytes and sinusoidal cells can not be distinguished by 
sucrose density gradient (Wattiaux et al., 1993). However, until now the lysosomal 
density has been studied only in cells from mature animals (1997; Wattiaux et al., 1993), 
and a possible lysosomal density shift in PCs and/or sinusoidal cells at very young age 
can not be ruled out. A lower density of lysosomes at this age could explain the observed 
phenomenon. 
A gradual increase in the density of the acid DNAse peak results in its co-elution with the 
radioactivity peak at old-age. The higher density of the radioactivity peak compared with 
the lysosomal marker peak in the younger animals can also be explained by tracer 
localisation in different subclasses of lysosomes. Breakdown of poorly degradable 
material takes place in late or terminal lysosomes (Kjeken et al., 1995). Incomplete 
digestion causes undigested material to accumulate and generate residual bodies, also 
called tertiary lysosomes, or dense bodies (Nixon and Cataldo, 1993; Schmucker and 
Sachs, 2002) that are denser than lysosomes (Roederer et al., 1989; Rome et al., 1979). 
Presumably at 5 weeks post-injection the remaining 14C-AGE-DP concentrates in the 
terminal part of the endosomal-lysosomal route i.e. in residual bodies. Gradual age-
related shifts of acid DNase to a higher density region could reflect increased proportion 
of residual bodies with age. The latter has been reported in hepatocytes, LSECs and KCs 
(de Leeuw et al., 1983; De Leeuw et al., 1990; De Priester et al., 1984; Schmucker and 
Sachs, 2002). Residual bodies also increase in diabetes when AGEs formation is 
accelerated (Giacomelli et al., 1980).  
 
Analysis of the hepatocellular distribution of administered 14C-AGE-BSA revealed that 
the ligand is taken up exclusively in the KCs and LSECs, the latter representing 
specialized scavenger endothelial cells with extraordinarily high pinocytic activity 
(Sorensen et al.). Interestingly, both cell types show decreased efficiency of 14C-AGE-DP 
elimination after puberty, suggesting that the post-pubertal decline in disposition of AGE-
DPs reflects a systemic age-related change. 
 
Blood concentration of 14C-AGE-DPs is very low (Fig.1) indicating their rapid kidney 
clearance. Thus, changes in the MW profile of urinary 14C-AGE-DPs reflect liver rather 
than kidney function. Very low MW 14C-AGE-DPs dominate in the urine soon after 
injection. With time, the proportion of higher MW 14C-AGE-DPs in the urine increases. 
This indicates that predominantly low MW 14C-AGE-DPs are excreted during the initial 
disposal phase whereas higher MW material is processed during the intermediate and 
terminal phases. Twenty-one known AGEs in free form, ranging from 220Da (carboxy 
methyl lysine; CML) to 545Da (Crosslines)(Ling et al., 1998; Niwa, 2006). Therefore, 
most of the urinary 14C-AGE-DPs at day 1 (Fig.5A) should be free-AGEs, whereas the 
majority of 14C-AGE-DPs appearing later consists of 14C-AGE-peptides.  
Pre-pubertal animals exhibit an increased ability to excrete very low and intermediate 
MW AGE-DPs. Note the broader MW spectrum (day1) and higher MW spectrum (days5 
and 18) in the pre-pubertal mice vs. other age groups. This is in accordance with the 
observation of increased proportion of AGE-DPs being removed in the fast phase and 
faster removal rate in intermediate and slow phases in the pre-pubertal group. The shift of 
urinary 14C-AGE-DPs towards higher MW is delayed at day 2 in the old-age group 
(Fig.5B), reflecting the absence of an initial removal phase in this group (Fig.2-insert and 
Tab.1).  
AGE-modified proteins are resistant to proteases (Miyata et al., 1997; Sell et al., 1996), 
which could account for the slow removal of 14C-AGE-BSA associated radioactivity from 
liver. It may be postulated that the different age-related abilities to discharge AGE-DPs 
reside in different levels of lysosomal enzymes in hepatic scavenger cells from pre- and 
postpubertal individuals. However, specific activities of most lysosomal enzymes are 
unchanged or increased with age in LSECs, KCs or PCs (de Leeuw et al., 1983; De 
Leeuw et al., 1990; De Priester et al., 1984; Zhang and Cuervo, 2008). In vitro generated 
AGEs are highly aggregated (Svistounov et al., 2003). However, as early as 24h post-
injection most radioactivity is associated with low MW material (SDS-PAGE of liver 
homogenates, not shown). This suggests that the liver scavenger cells are capable of 
degrading AGE-proteins but encounter problems with the excretion of AGE-DPs.  
It is unknown how AGE-DPs leave the scavenger cells after uptake. Theoretically, free-
AGEs and AGE-peptides of various size may find their way out of the lysosomes and 
cells by means of i) membrane transporters (present in both lysosomal end plasma 
membranes) (Forster and Lloyd, 1988); ii) free diffusion (Forster and Lloyd, 1988; 
Iveson et al., 1989), iii) retrograde transport along the endocytic pathway (Aniento et al., 
1993; Jahraus et al., 1994), or iv) lysosomal exocytosis (Tam et al.). When discussing the 
mechanism of how AGE-DPs are discharged from the liver scavenger cells, one should 
bear in mind that most – if not all - such studies have been carried out as short term 
(minutes – hours) experiments with cells or organelles in vitro, whereas in the present 
study the time scale is much greater (days-weeks), and takes place in the intact animal. 
Therefore, even low efficiency mechanisms such as free diffusion may be important. 
Nevertheless, the process termed lysosomal exocytosis, which has been shown to be a 
general pathway for cells to rid themselves of undegradable lysosomal waste contents 
(De Bruyn and Cho, 1986; Medina et al.; Tam et al.), appears as a likely exodus path for 
these non-degradable AGE-DPs.  
Since young-adult mice cannot be considered as aged, the marked decrease in the rate of 
AGE-DPs removal in these mice, compared with pre-pubertal animals can hardly be 
explained by age-related deterioration of this function. Therefore, the decline in AGE-
DPs removal rate in the young-adult group is likely to be a consequence of a 
physiological process but may in turn lead to waste accumulation and aging.  
In summary:  
Disposal of endocytosed AGE-DPs from the liver is a slow process. Elimination of these 
adducts from liver scavenger cells in mice is fastest in pre-pubertal animals and decreases 
significantly after sexual maturation. No major age-related changes are observed in the 
efficiency of liver disposal of AGEs from young-adult to middle-aged mice. However, 
senescence is associated with disappearance of the initial liver disposal phase.  
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Supplementary data  
This article contains supplementary information including supplementary experimental 
procedures, two supplementary figures and supplementary figure legends. 
 
Table 1 Pharmacokinetic parameters of 14C-AGE-BSA disposition from the liver of 
different age groups 
C is the coefficient of exponential model representing the distance from starting place to 
the bottom on the Y axis (expressed in % of injected dose).  
Half-life values are derived from the exponent of the model used to describe the data 
(expressed in weeks). 
Area under the curve (AUC) for each part of the curve is calculated as the C divided by 
the exponent (C/k) and representing exposure of liver to injected 14C-AGE-BSA 
(expressed in  % of dose per weeks). Total AUC is calculated as the sum of the AUC for 
each phase. 
Subscripts 1, 2 and 3 refer to the initial, intermediate and terminal phases respectively. 
Superscript indicates significance (p<0.05) in F-test vs. corresponding groups: pre-
pubertal (p), young-adult (a), middle-age (m) and old (o). 
Phases Parameters Pre-pubertal Young-adult Middle-age Old-age 
Initial C1  34 26 30 Absent 
half-life1 0.10 0.06 0.07 Absent 
AUC1 5.0 2.3 3.0 Absent 
Intermediate C2 34 vs. o 36 vs. o 36 vs. o 48 vs. p, a, m 
half-life2 0.51 vs. m 0.64 vs. o 0.78 vs. p, o 0.36 vs. a, m 
AUC2 25 33 41 25 
Terminal C3 3 vs. a, m, o 15 vs. p, m, o 10 vs. p, a, o 23 vs. p, a, m 
half-life3 3.28 vs. a, m 5.23 vs. p, o 6.31 vs. p, o 3.34 vs. a, m 
AUC3 14 91 68 103 
 AUC total 44 126 111 128 
 
 
Figure legends  
Figure 1 Anatomical distribution of intravenously injected 14C-AGE-BSA  
Mice from pre-pubertal, young-adult and old age groups were injected with 14C-AGE-
BSA (4.7µg; 2x106dpm), and killed at 1.5h, 24h, 1, 2, 3, 4, 5, or 8 weeks after injection 
for analyses of anatomical distribution of radioactivity. Results represent percentages of 
organ-associated radioactivity from total radioactivity recovered in listed organs at a 
given time point. Radioactivity in stomach, and small and large intestines were measured 
together with organ contents. *Value for empty urinary bladder, **value for gallbladder 
with bile. Data represent mean values ± SD (n = 22 per organ). Since no significant 
difference in relative anatomical distribution of radioactivity was observed between either 
the age groups or the time points after ligand administration, pooled data were plotted in 
this figure. 
 
Figure 2 14C-AGE hepatic disposal following uptake of injected 14C-AGE-BSA  
The fate of the 14C-AGE tracer in the liver of pre-pubertal (green triangles), young-adult 
(red squares), middle age (yellow rings) and old (blue diamonds) mice was followed for 
12 weeks after intravenous injection of 14C-AGE-BSA (4.7 µg, 2×106 dpm).  
Radioactivity retained in liver is given as percentage of injected radioactivity (% dose) 
and is plotted in a semi-logarithmic plot (log2-linear scale) up to 12 weeks after injection. 
The insert represents the linear plot (linear - linear scale) of the data up to 2 weeks after 
ligand administration. Mean ± SD shown (n ≤ 6 per time point). 
Each age group liver radioactivity–time profile was fitted to either 2-or 3-phase 
exponential models to describe the time course of liver radioactivity. These models have 
the mathematical form of  
A = C1.e-k1*t+C2.e-k2*t+C3.e-k3*t where A is the 14C-AGE-associated radioactivity in liver 
(expressed as % dose), C is the coefficient from the exponential model, k is the exponent 
and t is time after injection (weeks). Half-life is calculated as ln2/k. The subscript 1, 2 
and 3 refer to the initial, intermediate and terminal phases respectively. The AUC from 
each phase is calculated as C/k and the total AUC is the sum of the AUC for each phase. 
Curves are built from parameters obtained by fitting two-phase exponential decay (old 
group) and three phase exponential decay (pre-pubertal, young-adult, middle-aged 
groups) models to the data points. The model that best described the radioactivity 
disposal data was selected using the Akaike’s Information Criterion (AIC). 
 
Figure 3 Hepatocellular distribution of 14C-AGEs in pre-pubertal and young-adult 
mice  
Pre-pubertal and young-adult mice were injected intravenously with 14C-AGE-BSA. The 
animals were euthanized after 10 min (A) or 4 weeks (B) and radioactivity (dpm/million 
cells) was measured in solubilized cultures of purified parenchymal cells (PC), Kupffer 
cells (KC), and liver sinusoidal endothelial cells (LSECs). AGE-BSA injection dose: 9.4 
µg/animal; in the 10 min group this dose was achieved by mixing 2.35 µg 14C-AGE-BSA 
(1x106 dpm) with 7.05 µg non-radioactive AGE-BSA, while the 4 week group was 
injected with 9.4 µg of 14C-AGE-BSA (4x106 dpm). 
A) Radioactivity# in liver cells 10 min after ligand injection in 0.8 month old (open bars, 
n=7) and 3 month old mice (filled bars, n=6). #Adjusted values. 
B) Radioactivity in liver cells 4 weeks after ligand injection in 0.8 month old (open bars, 
n=6) and 3 month old mice (filled bars, n=8).  
* Significant difference (p<0.01) in 14C-radioactivity in corresponding cell types isolated 
from mice injected at 0.8 months and 3 months of age. Error bars: SD.  
#In Fig. 3A (10 min group) dpm values measured in samples were multiplied by four to 
reflect the real difference in AGE content in liver cells isolated at 10 min and 4 weeks 
after injection. 
 
Figure 4 Subcellular localization of 14C-AGEs  
14C-AGE-BSA (4.7 µg, 2 × 106 dpm) was injected intravenously in pre-pubertal (A), 
young-adult (B), middle-aged (C) and old (D) mice. Livers were surgically extracted, 
homogenized , and cellular compartments were separated on linear sucrose gradient 5 
weeks after 14C-AGE-BSA injection. Radioactivity and acid DNAse (a lysosomal 
marker(De Leeuw et al., 1990)) activity were measured in the sucrose gradient fractions.  
Acid DNAse indicates the location of lysosomes on the gradient. About 50% of this 
enzyme come from KCs and LSECs and the rest originates from PCs (Wattiaux et al., 
1993). Lysosomes from all three cell types normally banded at the same density on 
sucrose gradient (Wattiaux et al., 1993).  
All radioactive material in the gradient originates from KCs and LSECs.  
Results are presented as % of maximum detected radioactivity (squares, solid line) and % 
of maximum detected acid DNase activity (triangles, dashed line) in the fractions as a 
function of the gradient density. 
A- pre-pubertal; B- young-adult; C- middle-age and D- old-age groups.  
The radioactivity peak banded at virtually the same sucrose gradient density 1.223-
1.229g/ml in all age groups (panels A-D). Acid DNAse peak banded at density 1.193; 
1.202; 1.205 and 1.225g/ml in pre-pubertal; young-adult; middle-age and old-age groups 
respectively (panels A-D). 
 
Figure 5 Size distribution of 14C-AGE-DPs in urine 
Urine samples were collected 1 day (A), 2 days (B), 6 days (C) and 18 days (D) after 
intravenous injection of 14C-AGE-BSA (4.7 µg, 2 × 106 dpm, per animal).  
Size distribution of urinary 14C-AGE-DPs from pre-pubertal (n=4, green line), young-
adult (n=2, red line), middle-aged (n=2, yellow line) and old (n=1, blue line) mice was 
performed by size exclusion chromatography using Superdex peptide 10/300 GL column. 
MW were calculated from the standard curve generated by plotting the retention time of 
protein standards against their corresponding MW Results presented are representative 
chromatograms of one animal per age group at the different time points. 
The two x-axes represent MW distribution (Da, lower x-axis) and retention time (min, 
upper x-axis). Signal intensity is expressed as 14C radioactivity (% of maximum detected) 
is plotted along the y-axis. Vo - void volume of the column; Vtot - total volume of the 
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